PDF herunterladen
Horm Metab Res 2019; 51(12): 785-791
DOI: 10.1055/a-1062-9447
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Adherence to Teriparatide Treatment and Risk of Fracture: A Systematic Review and Meta-Analysis

Qing Chen
1   Department of Diabetes and Endocrinology, Affiliated Hospital of Southwest Medical University, Luzhou, China
2   Luzhou Key Laboratory of Cardiovascular and Metabolic Diseases, Luzhou, China
,
Man Guo
1   Department of Diabetes and Endocrinology, Affiliated Hospital of Southwest Medical University, Luzhou, China
2   Luzhou Key Laboratory of Cardiovascular and Metabolic Diseases, Luzhou, China
,
Xiumei Ma
1   Department of Diabetes and Endocrinology, Affiliated Hospital of Southwest Medical University, Luzhou, China
2   Luzhou Key Laboratory of Cardiovascular and Metabolic Diseases, Luzhou, China
,
Yueli Pu
1   Department of Diabetes and Endocrinology, Affiliated Hospital of Southwest Medical University, Luzhou, China
2   Luzhou Key Laboratory of Cardiovascular and Metabolic Diseases, Luzhou, China
,
Yang Long
1   Department of Diabetes and Endocrinology, Affiliated Hospital of Southwest Medical University, Luzhou, China
2   Luzhou Key Laboratory of Cardiovascular and Metabolic Diseases, Luzhou, China
,
Yong Xu
1   Department of Diabetes and Endocrinology, Affiliated Hospital of Southwest Medical University, Luzhou, China
2   Luzhou Key Laboratory of Cardiovascular and Metabolic Diseases, Luzhou, China
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 04. Februar 2019

accepted 05. November 2019

Publikationsdatum:
11. Dezember 2019 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

To conduct a retrospective systematic review and meta-analysis of studies investigating the fracture risk among adherence versus non-adherence patients to treatment for osteoporosis. Cohort studies involving adherence to specifically Teriparatide treatment and the risk of fracture, published from inception to June 10 2019, were identified through PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and Scopus database of Systematic Reviews. Five eligible cohort studies were included for analysis. Overall, adherence, compared with nonadherence, had a significant 28% reduction in the risk of all fractures, an 49% reduction in the risk of hip fracture and an 26% reduction in the risk of non-vertebral fracture. Subgroup analyses showed that treatment compliant North American patients had a lower incidence of fracture than treatment compliant Asian patients. The effect size associated with adherence showed no difference with non-adherence when the analysis was limited to a small sample size (<10 000 patients). The findings of this retrospective review indicate that high compliance of Teriparatide treatment result in a decreased risk of fracture, particularly in North American treatment adherence, compared with Asian treatment adherence. Improvement of treatment adherence in patients with osteoporosis should be considered through various means in clinical practice.

Key words

teriparatide - adherence - osteoporosis - fractures - meta-analysis
 

  • References

  • 1 Bonjour JP, Ammann P, Rizzoli R. Importance of preclinical studies in the development of drugs for treatment of osteoporosis: a review related to the 1998 WHO guidelines. Osteoporos Int 1999; 9: 379-393
    CrossrefPubMedGoogle Scholar
  • 2 Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet (London, England) 2002; 359: 1761-1767
    CrossrefPubMedGoogle Scholar
  • 3 Ioannidis G, Papaioannou A, Hopman WM. et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 2009; 181: 265-271
    CrossrefPubMedGoogle Scholar
  • 4 Burge R, Dawson-Hughes B, Solomon DH. et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Mineral Res 2007; 22: 465-475
    CrossrefPubMedGoogle Scholar
  • 5 Tarride JE, Hopkins RB, Leslie WD. et al. The burden of illness of osteoporosis in Canada. Osteoporos Int 2012; 23: 2591-2600
    CrossrefPubMedGoogle Scholar
  • 6 Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol 2017; 5: 898-907
    CrossrefPubMedGoogle Scholar
  • 7 Black DM, Abrahamsen B, Bouxsein ML. et al. Atypical femur fractures: Review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev 2019; 40: 333-368
    CrossrefPubMedGoogle Scholar
  • 8 Gomberg SJ, Wustrack RL, Napoli N. et al. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 2011; 96: 1627-1632
    CrossrefPubMedGoogle Scholar
  • 9 Hodsman AB, Bauer DC, Dempster DW. et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26: 688-703
    CrossrefPubMedGoogle Scholar
  • 10 Diez-Perez A, Marin F, Eriksen EF. et al. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis. Bone 2019; 120: 1-8
    CrossrefPubMedGoogle Scholar
  • 11 Belhassen M, Confavreux CB, Cortet B. et al. Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up. Osteoporos Int 2017; 28: 853-862
    CrossrefPubMedGoogle Scholar
  • 12 Reyes C, Tebe C, Martinez-Laguna D. et al. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos Int 2017; 28: 2997-3004
    CrossrefPubMedGoogle Scholar
  • 13 Cheng LI, Durden E, Limone B. et al. Persistance and compliance with osteroporosis therapies among women in a commercially insured population in the United States. J Manag Care Special Pharm 2015; 21: 824-833 833a
    PubMedGoogle Scholar
  • 14 Ziller V, Kostev K, Kyvernitakis I. et al. Persistence and compliance of medications used in the treatment of osteoporosis–analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Therap 2012; 50: 315-322
    PubMedGoogle Scholar
  • 15 Merino EM, Álvarez-Gutierrez A, Álvarez CH. et al. Persistence to anti-osteoporosis treatments in primary care patients recorded in the Spanish electronic database BIFAP. NDORMS 2016; 25: 187-188
    PubMedGoogle Scholar
  • 16 Carbonell-Abella C, Pagèscastellà A, Nogués X. et al. Persistence with different antiosteoporosis medications: A population-based cohort study. Osteoporos Int 2013; 24: S187-S188
    CrossrefPubMedGoogle Scholar
  • 17 Siris ES, Selby PL, Saag KG. et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009; 122: S3-S13
    PubMedGoogle Scholar
  • 18 Ross S, Samuels E, Gairy K. et al. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 2011; 14: 571-581
    CrossrefPubMedGoogle Scholar
  • 19 Imaz I, Zegarra P, Gonzalez-Enriquez J. et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2010; 21: 1943-1951
    CrossrefPubMedGoogle Scholar
  • 20 Hutton B, Salanti G, Caldwell DM. et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162: 777-784
    CrossrefPubMedGoogle Scholar
  • 21 Wells G, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013
    PubMed
  • 22 Zhao Y, Johnston SS, Smith DM. et al. Association between teriparatide adherence and healthcare utilization and costs among hip fracture patients in the United States. Bone 2014; 60: 221-226
    CrossrefPubMedGoogle Scholar
  • 23 Chan DC, Chang CH, Lim LC. et al. Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database. Osteoporos Int 2016; 27: 2855-2865
    CrossrefPubMedGoogle Scholar
  • 24 Burge RT, Disch DP, Gelwicks S. et al. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States. Osteoporos Int 2017; 28: 799-809
    CrossrefPubMedGoogle Scholar
  • 25 Burge R, Sato M, Sugihara T. Real-world clinical and economic outcomes for daily teriparatide patients in Japan. J Bone Mineral Metab 2016; 34: 692-702
    CrossrefPubMedGoogle Scholar
  • 26 Bonafede MM, Shi N, Bower AG. et al. Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis. Osteoporos Int 2015; 26: 1203-1212
    CrossrefPubMedGoogle Scholar
  • 27 Rajzbaum G, Jakob F, Karras D. et al. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin 2008; 24: 377-384
    CrossrefPubMedGoogle Scholar
  • 28 Silverman S, Miller P, Sebba A. et al. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporos Int 2013; 24: 2309-2317
    CrossrefPubMedGoogle Scholar
  • 29 Napoli N, Langdahl BL, Ljunggren O. et al. Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European Extended Forsteo(R) Observational Study (ExFOS). Calcif Tissue Int 2018; 103: 359-371
    CrossrefPubMedGoogle Scholar
  • 30 Aloumanis K, Karras D, Drossinos V. et al. Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study. J Osteoporos 2011; 2011: 510398
    PubMedGoogle Scholar
  • 31 Fahrleitner-Pammer A, Langdahl BL, Marin F. et al. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int 2011; 22: 2709-2719
    CrossrefPubMedGoogle Scholar
  • 32 Langdahl BL, Ljunggren O, Benhamou CL. et al. Fracture rate, quality of life and back pain in patients with osteoporosis treated with teriparatide: 24-Month results from the Extended Forsteo Observational Study (ExFOS). Calcif Tissue Int 2016; 99: 259-271
    CrossrefPubMedGoogle Scholar
  • 33 Soen S, Fujiwara S, Takayanagi R. et al. Japan Fracture Observational Study (JFOS): Patient characteristics and interim data on the use of daily teriparatide in Japanese patients with osteoporosis. Curr Med Res Opin 2015; 31: 1771-1779
    CrossrefPubMedGoogle Scholar
  • 34 Miller PD, Silverman SL, Gold DT. et al. Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study. Osteoporos Int 2006; 17: 85-90
    CrossrefPubMedGoogle Scholar
  • 35 Soen S, Fujiwara S, Takayanagi R. et al. Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS). Curr Med Res Opin 2017; 33: 2049-2056
    CrossrefPubMedGoogle Scholar
  • 36 Langdahl BL, Silverman S, Fujiwara S. et al. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone 2018; 116: 58-66
    CrossrefPubMedGoogle Scholar
  • 37 Langdahl BL, Rajzbaum G, Jakob F. et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009; 85: 484-493
    CrossrefPubMedGoogle Scholar
  • 38 Silverman S, Langdahl BL, Fujiwara S. et al. Reduction of hip and other fractures in patients receiving teriparatide in real-world clinical practice: Integrated analysis of four prospective observational studies. Calcif Tissue Int 2019; 104: 193-200
    CrossrefPubMedGoogle Scholar
  • 39 Ljunggren O, Benhamou CL, Dekker J. et al. Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS). Curr Med Res Opin 2014; 30: 1607-1616
    CrossrefPubMedGoogle Scholar
  • 40 Rajzbaum G, Grados F, Evans D. et al. Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study. Joint Bone Spine Rev Rhumat 2014; 81: 69-75
    PubMedGoogle Scholar
  • 41 Cauley JA. Defining ethnic and racial differences in osteoporosis and fragility fractures. Clin Orthopaed Relat Res 2011; 469: 1891-1899
    CrossrefPubMedGoogle Scholar
  • 42 Khandelwal S, Chandra M, Lo JC. Clinical characteristics, bone mineral density and non-vertebral osteoporotic fracture outcomes among post-menopausal U.S. South Asian Women. Bone 2012; 51: 1025-1028
    CrossrefPubMedGoogle Scholar